​
​

Innoviva (INVA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Innoviva Revenue Highlights

Latest Revenue (Y)

$310.46M

Latest Revenue (Q)

$103.35M

Main Segment (Y)

Royalty

Innoviva Revenue by Period

Innoviva Revenue by Year

DateRevenueChange
2023-12-31$310.46M-6.30%
2022-12-31$331.34M-15.45%
2021-12-31$391.87M16.35%
2020-12-31$336.79M29.03%
2019-12-31$261.02M0.00%
2018-12-31$261.00M20.16%
2017-12-31$217.22M62.63%
2016-12-31$133.57M147.58%
2015-12-31$53.95M539.74%
2014-12-31$8.43M77.24%
2013-12-31$4.76M-96.50%
2012-12-31$135.76M453.84%
2011-12-31$24.51M1.19%
2010-12-31$24.22M-0.62%
2009-12-31$24.37M5.53%
2008-12-31$23.10M4.97%
2007-12-31$22.00M12.33%
2006-12-31$19.59M62.49%
2005-12-31$12.05M34.83%
2004-12-31$8.94M147.99%
2003-12-31$3.60M2210.90%
2002-12-31$156.00K100.00%
2001-12-31-100.00%
2000-12-31--

Innoviva generated $310.46M in revenue during NA 2023, up -6.30% compared to the previous quarter, and up 118.95% compared to the same period a year ago.

Innoviva Revenue by Quarter

DateRevenueChange
2024-06-30$103.35M27.67%
2024-03-31$80.95M-9.32%
2023-12-31$89.27M32.73%
2023-09-30$67.26M-16.96%
2023-06-30$80.99M6.05%
2023-03-31$76.37M16.06%
2022-12-31$65.80M-2.16%
2022-09-30$67.26M-37.85%
2022-06-30$108.22M20.17%
2022-03-31$90.06M-16.36%
2021-12-31$107.68M10.03%
2021-09-30$97.86M-2.92%
2021-06-30$100.81M17.88%
2021-03-31$85.52M-5.48%
2020-12-31$90.48M2.01%
2020-09-30$88.69M12.35%
2020-06-30$78.95M0.34%
2020-03-31$78.68M3.56%
2019-12-31$75.97M15.54%
2019-09-30$65.75M2.57%
2019-06-30$64.11M16.17%
2019-03-31$55.18M-30.90%
2018-12-31$79.86M29.47%
2018-09-30$61.68M-8.06%
2018-06-30$67.09M28.08%
2018-03-31$52.38M-24.65%
2017-12-31$69.52M42.92%
2017-09-30$48.64M-16.94%
2017-06-30$58.56M44.63%
2017-03-31$40.49M-7.15%
2016-12-31$43.61M30.93%
2016-09-30$33.31M2.58%
2016-06-30$32.47M34.32%
2016-03-31$24.18M5.87%
2015-12-31$22.84M68.38%
2015-09-30$13.56M27.28%
2015-06-30$10.65M54.51%
2015-03-31$6.90M-5.27%
2014-12-31$7.28M628.73%
2014-09-30$999.00K6.96%
2014-06-30$934.00K466.06%
2014-03-31$165.00K-89.99%
2013-12-31$1.65M275.40%
2013-09-30$439.00K-66.92%
2013-06-30$1.33M-1.26%
2013-03-31$1.34M-76.82%
2012-12-31$5.80M305.45%
2012-09-30$1.43M-
2012-06-30$1.43M-98.87%
2012-03-31$127.10M2270.37%
2011-12-31$5.36M-16.62%
2011-09-30$6.43M0.66%
2011-06-30$6.39M0.92%
2011-03-31$6.33M-8.80%
2010-12-31$6.94M30.93%
2010-09-30$5.30M-15.36%
2010-06-30$6.26M9.63%
2010-03-31$5.71M49.50%
2009-12-31$3.82M-30.70%
2009-09-30$5.51M0.40%
2009-06-30$5.49M-42.45%
2009-03-31$9.54M60.48%
2008-12-31$5.95M-0.87%
2008-09-30$6.00M8.97%
2008-06-30$5.50M-2.48%
2008-03-31$5.64M0.27%
2007-12-31$5.63M-

Innoviva generated $103.35M in revenue during Q2 2024, up 27.67% compared to the previous quarter, and up 135.33% compared to the same period a year ago.

Innoviva Revenue Breakdown

Innoviva Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 20
Product$60.62M$19.69M-
Royalty$238.85M$311.64M$73.09M
License$1.60M--
License Revenue$11.00M--
Collaborative Arrangements--$10.00M

Innoviva's latest annual revenue breakdown by segment (product or service), as of Dec 23: Royalty (76.54%), Product (19.42%), License Revenue (3.52%), and License (0.51%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21
Product$27.82M$21.65M$19.08M$19.68M$13.70M$15.73M$11.51M$14.59M$5.11M----
Royalty$57.06M$63.74M$58.41M$66.17M$53.56M$62.27M$56.86M$51.22M$42.72M$29.31M$35.59M$26.39M-
License Revenue$4.63M$14.51M---$3.00M$8.00M------
License----$1.60M--------

Innoviva's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Royalty (63.74%), Product (31.08%), and License Revenue (5.17%).

Innoviva Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
INCYIncyte$3.70B$962.99M
ARGXargenx SE$1.23B$401.00M
HRMYHarmony Biosciences$582.02M$186.04M
FOLDAmicus Therapeutics$399.36M$141.52M
AMLXAmylyx Pharmaceuticals$380.79M$416.00K
APLSApellis Pharmaceuticals$366.28M$176.57M
DNLIDenali Therapeutics$330.53M-
INVAInnoviva$310.46M$103.35M
HOOKHOOKIPA Pharma$20.13M-
LIFEaTyr Pharma$353.00K$235.00K
XFORX4 Pharmaceuticals-$560.00K
PDSBPDS Bio--
DAWNDay One Biopharmaceuticals-$20.07M
ABOSAcumen Pharmaceuticals--
INZYInozyme Pharma--
ELEVElevation Oncology--
TERNTerns Pharmaceuticals--
EFTReFFECTOR Therapeutics--

INVA Revenue FAQ

What is Innoviva’s yearly revenue?

Innoviva's yearly revenue for 2023 was $310.46M, representing a decrease of -6.30% compared to 2022. The company's yearly revenue for 2022 was $331.34M, representing a decrease of -15.45% compared to 2021. INVA's yearly revenue for 2021 was $391.87M, representing an increase of 16.35% compared to 2020.

What is Innoviva’s quarterly revenue?

Innoviva's quarterly revenue for Q2 2024 was $103.35M, a 27.67% increase from the previous quarter (Q1 2024), and a 27.61% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $80.96M, a -9.32% decrease from the previous quarter (Q4 2023), and a 6.00% increase year-over-year (Q1 2023). INVA's quarterly revenue for Q4 2023 was $89.27M, a 32.73% increase from the previous quarter (Q3 2023), and a 35.67% increase year-over-year (Q4 2022).

What is Innoviva’s revenue growth rate?

Innoviva's revenue growth rate for the last 3 years (2021-2023) was -20.77%, and for the last 5 years (2019-2023) was 18.94%.

What are Innoviva’s revenue streams?

Innoviva's revenue streams in c 23 are Product, Royalty, License, and License Revenue. Product generated $60.62M in revenue, accounting 19.42% of the company's total revenue, up 207.79% year-over-year. Royalty generated $238.85M in revenue, accounting 76.54% of the company's total revenue, down -23.36% year-over-year. License generated $1.6M in revenue, accounting 0.51% of the company's total revenue License Revenue generated $11M in revenue, accounting 3.52% of the company's total revenue

What is Innoviva’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Innoviva was Royalty. This segment made a revenue of $238.85M, representing 76.54% of the company's total revenue.